Vernakalant

Vernakalant

Clinical data
Trade names	Brinavess
Other names	RSD1235
Routes of administration	Intravenous,[1]
ATC code	C01BG11 (WHO)
Legal status
Legal status	CA: ℞-only[2] EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	low
Metabolism	CYP2D6, glucuronidation
Elimination half-life	3–5.5 hours
Identifiers
IUPAC name (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl) ethoxy]cyclohexyl}pyrrolidin-3-ol
CAS Number	794466-70-9 Y [https://commonchemistry.cas.org/detail?cas_rn=748810-28-8&title= 748810-28-8 (HCl) 748810-28-8 (HCl)]
PubChem CID	9930049
DrugBank	DB06217 Y
ChemSpider	8105680 N
UNII	9G468C8B13
KEGG	D06665
CompTox Dashboard (EPA)	DTXSID60229659
ECHA InfoCard	100.121.790
Chemical and physical data
Formula	C20H31NO4
Molar mass	349.471 g·mol−1
3D model (JSmol)	Interactive image
SMILES O(c1ccc(cc1OC)CCO[C@@H]3CCCC[C@H]3N2CC[C@@H](O)C2)C
InChI InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1 N Key:VBHQKCBVWWUUKN-KZNAEPCWSA-N N
NY (what is this?)  (verify)

Vernakalant, sold under the brand name Brinavess, is a class III antiarrhythmic drug for the acute conversion of atrial fibrillation, a kind of irregular heartbeat, in form of an intravenous infusion. It has been approved for use in the European Union and the United Kingdom since 2010. The US Food and Drug Administration denied approval in 2008 and 2019.